

Aaron C Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/859514/publications.pdf>

Version: 2024-02-01

16
papers

771
citations

759233

12
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

1088
citing authors

#	ARTICLE	IF	CITATIONS
1	Palladium-Catalyzed Synthesis of (Hetero)Aryl Alkyl Sulfones from (Hetero)Aryl Boronic Acids, Unactivated Alkyl Halides, and Potassium Metabisulfite. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 13571-13575.	13.8	180
2	Structural Basis for AMPK Activation: Natural and Synthetic Ligands Regulate Kinase Activity from Opposite Poles by Different Molecular Mechanisms. <i>Structure</i> , 2014, 22, 1161-1172.	3.3	159
3	Discovery and Preclinical Characterization of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1 <i>H</i> -indole-3-carboxylic Acid (PF-06409577), a Direct Activator of Adenosine Monophosphate-activated Protein Kinase (AMPK), for the Potential Treatment of Diabetic Nephropathy. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8068-8081.	6.4	98
4	Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13546-13560.	6.4	43
5	Spirolactam-Based Acetyl-CoA Carboxylase Inhibitors: Toward Improved Metabolic Stability of a Chromanone Lead Structure. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 7110-7119.	6.4	40
6	Discovery of Fragment-Derived Small Molecules for <i>In Vivo</i> Inhibition of Ketohexokinase (KHK). <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7835-7849.	6.4	35
7	Discovery of an <i>In Vivo</i> Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 1128-1133.	2.8	33
8	Discovery of Orally Bioavailable Selective Inhibitors of the Sodium-Phosphate Cotransporter NaPi2a (SLC34A1). <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 440-445.	2.8	24
9	Chemical Probe Identification Platform for Orphan GPCRs Using Focused Compound Screening: GPR39 as a Case Example. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 1079-1084.	2.8	19
10	Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10879-10896.	6.4	19
11	Two Scalable Syntheses of <i>S</i> -2-Methylazetidione. <i>Journal of Organic Chemistry</i> , 2016, 81, 3031-3036.	3.2	13
12	Optimization of Metabolic and Renal Clearance in a Series of Indole Acid Direct Activators of 5'-Adenosine Monophosphate-Activated Protein Kinase (AMPK). <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2372-2383.	6.4	13
13	Evolution of the Synthesis of AMPK Activators for the Treatment of Diabetic Nephropathy: From Three Preclinical Candidates to the Investigational New Drug PF-06409577. <i>Organic Process Research and Development</i> , 2018, 22, 681-696.	2.7	10
14	Decarbonylative Pd-Catalyzed Suzuki Cross-Coupling for the Synthesis of Structurally Diverse Heterobiaryls. <i>Organic Letters</i> , 2022, 24, 1678-1683.	4.6	10
15	Scalable, Telescoped Hydrogenolysis-Enzymatic Decarboxylation Process for the Asymmetric Synthesis of \pm -Heteroaryl Propionic Acids. <i>Organic Process Research and Development</i> , 2021, 25, 421-426.	2.7	9
16	Synthesis of \pm -Heteroaryl Propionic Esters by Palladium-Catalyzed \pm -Heteroarylation of Silyl Ketene Acetals. <i>Organic Letters</i> , 2021, 23, 6439-6443.	4.6	5